FLASH NEWS LIVE

VALANX Biotech secures €3 million to advance LIV-1 ADC for metastatic triple-negative breast cancer

VALANX Biotech secures €3 million to advance LIV-1 ADC for metastatic triple-negative breast cancer

VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, today announced it has secured €3 million to advance its lead antibody-drug conjugate (ADC) program.

Read Full Article →

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.
Instagram Meta X LinkedIn Whatsapp